Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Controversies in primary CNS lymphoma.

Lauren E Abrey1

  • 1Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, NY 10021, USA. abreyl@mskcc.org

Expert Review of Neurotherapeutics
|July 20, 2005
PubMed
Summary

Primary CNS lymphoma, a cancer of the brain and central nervous system, shows unique sensitivity to chemotherapy and radiation. Despite this, patient outcomes remain poor, highlighting the need for optimized treatment strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Framework for Statistical Parametric Mapping of the Interactions between Glioblastoma Location, Treatment, Prognostic Variables, and Survival Using a Phase III Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

Towards more Diversity in Neuro-oncology Leadership-the DivINe Initiative.

Neuro-oncology·2023
Same author

Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2023
Same author

Incidence, molecular characteristics, and imaging features of "clinically-defined pseudoprogression" in newly diagnosed glioblastoma treated with chemoradiation.

Journal of neuro-oncology·2022
Same author

Leveraging external data in the design and analysis of clinical trials in neuro-oncology.

The Lancet. Oncology·2021

Area of Science:

  • Neuro-oncology
  • Hematology
  • Cancer Research

Background:

  • Primary CNS lymphoma (PCNSL) is a rare non-Hodgkin's lymphoma exclusively affecting the central nervous system.
  • PCNSL exhibits distinct chemo- and radiosensitivity compared to other brain tumors.
  • Despite treatment advancements, PCNSL patient outcomes lag behind those with similar lymphomas.

Purpose of the Study:

  • To review current understanding and treatment approaches for primary CNS lymphoma.
  • To identify key challenges and unanswered questions in PCNSL management.
  • To explore strategies for improving patient outcomes in PCNSL.

Main Methods:

  • Review of prospective studies on high-dose methotrexate-based regimens.
  • Analysis of treatment outcomes with or without whole-brain radiotherapy.
  • Synthesis of existing literature on primary CNS lymphoma management.

Main Results:

  • High-dose methotrexate has shown efficacy in improving PCNSL outcomes.
  • The role and necessity of whole-brain radiotherapy in conjunction with chemotherapy require further clarification.
  • Significant disparities persist in the outcomes of PCNSL patients compared to other lymphoma subtypes.

Conclusions:

  • Primary CNS lymphoma treatment remains complex, with ongoing debates regarding optimal therapeutic protocols.
  • Further research is essential to refine treatment strategies and improve survival rates for PCNSL patients.
  • Personalized treatment approaches are needed to address the unique challenges of primary CNS lymphoma.

Related Experiment Videos